Vutrisiran

• CAT Number: I045370
• CAS Number: 1867157-35-4
• Molecular Weight: 16345 (AS: 7556.3; SS: 8788.7 )
• Purity: 98%
• Target: Transthyretin messenger RNA (TTR mRNA)
• Target Protein: P02766
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.

Vutrisiran（Cat No.:I045370）is a small interfering RNA (siRNA) therapeutic used to treat hereditary transthyretin-mediated amyloidosis (hATTR), a progressive disease caused by misfolded transthyretin (TTR) proteins. Vutrisiran works by silencing the TTR gene, reducing the production of both mutant and wild-type TTR proteins in the liver. This helps to prevent the accumulation of amyloid deposits in tissues, which can cause organ dysfunction. Administered via subcutaneous injection, Vutrisiran offers an effective, long-lasting treatment option that can help to slow disease progression and improve quality of life in hATTR patients.

Reference

[1]. Bahru A Habtemariam, et al. Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clin Pharmacol Ther. 2021 Feb;109(2):372-382.
[Content Brief]